

Blood DNA Methylation Signature for Incident Dementia: Evidence from Longitudinal Cohorts

Wei Zhang¹, Juan I. Young^{2,3}, Lissette Gomez³, Michael A. Schmidt^{2,3}, David Lukacsovich¹, Brian W. Kunkle^{2,3}, Xi Chen^{1,4}, Eden R. Martin^{2,3}, Lily Wang^{1,2,3,4*}

¹ Division of Biostatistics, Department of Public Health Sciences, University of Miami, Miller School of Medicine, Miami, FL 33136, USA

² Dr. John T Macdonald Foundation Department of Human Genetics, University of Miami, Miller School of Medicine, Miami, FL 33136, USA

³ John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL 33136, USA

⁴ Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL 33136, USA

* To whom correspondence should be addressed.

Corresponding Address:

Lily Wang
Soffer Clinical Research Ctr
University of Miami School of Medicine
1120 NW 14th St
Miami, Florida 33136-2107
lily.wang@miami.edu

Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (<http://adni.loni.usc.edu>). As such, the ADNI investigators contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators is available at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

ABSTRACT

INTRODUCTION Alzheimer's disease and related dementias pose a significant public health challenge, especially as the population ages. Dementia cases are often underreported, highlighting the need to identify individuals at risk early. However, distinguishing between molecular changes that precede dementia onset and those resulting from the disease is challenging with cross-sectional studies.

METHODS To address this, we studied blood DNA methylation (DNAm) differences and incident dementia in two large longitudinal cohorts: the Offspring cohort of the Framingham Heart Study (FHS) and the Alzheimer's Disease Neuroimaging Initiative (ADNI) study. We analyzed blood DNAm samples from over 1,000 cognitively unimpaired subjects.

RESULTS FHS participants (n = 907) were followed for up to 7.72 years after blood sample collection at Exam 9; ADNI participants (n = 216) were followed for up to 11.11 years after their initial visits. The mean ages at sample collection were 72.03 years in FHS and 76.73 years in ADNI. Meta-analysis of results from Cox regression models identified 44 CpGs and 44 differentially methylated regions consistently associated with time to dementia in both cohorts. Our integrative analysis identified early processes in dementia, such as immune responses and metabolic dysfunction. Validations with two independent datasets, the Australian Imaging, Biomarkers, and Lifestyle (AIBL) study and the AddNeuroMed study, showed significant discriminatory classification of dementia samples versus controls using methylation risk scores based on the 44 dementia-associated CpGs.

DISCUSSION These findings demonstrate that DNA methylation offers a promising pathway for early detection and prevention of dementia in at-risk populations.

BACKGROUND

Alzheimer's disease and related dementias (ADRD) are a major public health problem with a substantial economic burden¹. ADRD currently affects 8.1 million to 10.8 Americans in the United States², and this number is projected to rise as the population ages. The escalating healthcare demands of ADRD underscore the critical need for effective prevention, early diagnosis, and management approaches.

Given the difficulty in halting neurodegenerative processes once they begin, it is imperative to develop biomarkers that could identify individuals at high risk for developing AD while they are still cognitively unimpaired (CU). Such biomarkers can facilitate personalized medicine and the implementation of preventive lifestyle interventions, potentially delaying the onset of dementia. Recent studies showed that delaying the onset of dementia by only one year in the 70-74-year-old group could reduce prevalence by more than 10%³.

DNA methylation (DNAm) is an epigenetic mechanism influenced by both genetics and environment. Methylated DNA is relatively stable and can be easily detected, thus serving as an excellent source of biomarkers⁴. We and others have shown that DNAm is integrally involved in Alzheimer's dementia (AD)⁵⁻¹². Moreover, several recent studies demonstrated DNAm differences could be detected in blood samples of AD subjects¹³⁻¹⁸. In particular, our recent analysis of two large clinical AD datasets (ADNI and AIBL) revealed a number of blood DNAm differences consistently associated with AD diagnosis in both cohorts⁸.

To develop biomarkers that can assess individual risk for dementia, it's important to distinguish between DNAm changes that precede dementia onset and those that result from the disease. To date, most studies of DNAm in dementia have used a cross-sectional design^{7,8, 17-19} with only a few using the longitudinal design. Encouragingly, two recent longitudinal studies detected DNAm changes in the blood several years before the onset of dementia symptoms²⁰⁻²³. However, these studies were limited by their small sample sizes.

Here we studied DNAm and incident dementia by meta-analyzing two large longitudinal datasets from the Framingham Heart Study (FHS) and the Alzheimer's Disease Neuroimaging Initiative (ADNI) studies, with a total of more than 1000 samples. All samples included in this meta-analysis were measured using the same Infinium MethylationEPIC Beadchip platform, and each dataset was analyzed using a uniform analytical pipeline. We identified CpGs and differentially methylated regions (DMRs) consistently associated with dementia in both cohorts. Moreover, we also performed comparative analysis incorporating results from integrative analysis of DNAm in the blood with gene expression, genetic variants, and brain DNA methylation. These analyses, along with gene set enrichment analysis, highlighted DNAm differences associated with immune responses and metabolic dysfunction in dementia. In addition to corroborating

findings from previous studies using a cross-sectional design, our analysis also nominated a number of novel DNAm differences, emphasizing the importance of using a longitudinal design to identify DNAm differences with a temporal relationship to the disease.

METHODS

Study datasets for meta-analysis

For the FHS data collected at Exam 9 (denoted FHS9 hereafter), DNA methylation data and dementia ascertainment were obtained from the dbGap database (accessions: phs000974.v5.p4 and pht010750.v2.p14). For the ADNI dataset, DNA methylation data and the dementia status of the subjects were obtained from the ADNI study website (adni.loni.usc.edu). The endpoint of this study is dementia onset. The follow-up period was from the time of blood sample collection for DNA methylation measurement to the time of dementia onset. Follow-up was censored at the time of loss to follow-up, non-dementia death, or the final day of study follow-up.

Pre-processing of DNA methylation data

DNA methylation samples from both FHS9 and ADNI were measured using the same Illumina HumanMethylation EPIC v1 bead chips. Supplementary Table 1 shows the number of CpGs and samples at each quality control (QC) step. The FHS9 and ADNI datasets were pre-processed separately. For each dataset, the QC of probes involved several steps. First, we selected probes with a detection P -value < 0.01 in 90% or more of the samples. A small P -value indicates a significant difference between the signals in the probes and the background noise. Next, we selected probes that start with "cg", and using the function `rmSNPandCH` from the `DMRcate` R package, we removed probes that are located on X and Y chromosomes, are cross-reactive²⁴, or located close to single nucleotide polymorphism (SNPs) (i.e., an SNP with minor allele frequency (MAF) ≥ 0.01 was present in the last five base pairs of the probe).

For QC of the samples, we first removed samples with bisulfite conversion rate lower than 85%, as well as samples for which the DNAm predicted sex status differed from the recorded sex status. The sex prediction was performed using the `getSex` function from the `minfi` R package. In addition, we performed principal component analysis (PCA) using the 50,000 most variable CpGs to identify outliers. Samples outside the range of ± 3 standard deviations from the mean of PC1 and PC2 were excluded. We removed

samples from subjects with dementia or MCI diagnosis at Exam 9 or any earlier exams in FHS, or at initial visit to ADNI.

The quality-controlled data was next normalized using the `dasen` method, as implemented in the `watermelon` R package. Immune cell type proportions (B lymphocytes, natural killer cells, CD4+ T cells, CD8+ T cells, monocytes, neutrophils, and eosinophils) were estimated using the `EpiDISH` R package. As in previous blood-based DNAm studies^{7,8,25}, granulocyte proportions were computed as the sum of neutrophils and eosinophils proportions since both neutrophils and eosinophils are classified as granular leukocytes. To correct batch effects from methylation plates, we used the `BEclear` R package²⁶.

Association of DNA methylation at individual CpGs with dementia

To evaluate the relationship between incident dementia and DNA methylation, we conducted Cox proportional regression analyses on both FHS and ADNI datasets separately, via the `coxph` function in the `survival` R package. For the FHS dataset, we used the model: `surv(incident dementia, follow-up time) ~ methylation.beta + age + sex + immune cell-type proportions (B, NK, CD4T, Mono, Gran)` (Model 1). For the ADNI dataset, given the smaller sample size, we only included the first two principal components (PCs) of the immune cell-type proportions, which explained 90.0% variances in estimated immune cell-type proportions. Specifically, we fitted the model `Surv(incident dementia, follow-up time) ~ methylation.beta + age + sex + PC1 + PC2`.

Inflation assessment and correction

Genomic inflation factors (lambda values) were estimated using both the conventional approach²⁷ and the *bacon* method²⁸, which was proposed specifically for EWAS. For the FHS and ADNI datasets, the estimated bias was -0.009 and 0.041, respectively. For the estimated inflation, the lambda values (λ) using the conventional approach were 1.424 and 1.005, while the lambda values based on the *bacon* approach (λ .*bacon*) were 1.176 and 0.986 for the FHS and ADNI datasets, respectively (Supplementary Table 2).

We next applied genomic correction using the *bacon* method²⁸, as implemented in the *bacon* R package, to obtain *bacon*-corrected effect sizes, standard errors, and *P*-values for each dataset. After *bacon* correction, the estimated bias were 4.78×10^{-4} and -6.18×10^{-4} , and the estimated inflation factors were $\lambda = 1.03$ and 1.029, and λ .*bacon* = 1.01 and 1.00 for the FHS and ADNI datasets, respectively.

Meta-analysis

To meta-analyze individual CpG results across both the FHS9 and ADNI datasets, we used the inverse-variance weighted fixed-effects model, implemented in the meta R package. The methylation beta values were rescaled into z-scores so that the estimated hazard ratios correspond to an increase in dementia risk associated with a one standard deviation increase in beta values. To correct for multiple comparisons, we computed the false discovery rate (FDR). We considered CpGs with an FDR less than 5% in meta-analysis of the FHS9 and ADNI datasets, with a consistent direction of change in estimated effect sizes, and a nominal *P*-value less than 0.05 in both datasets as statistically significant.

Differentially methylated regions analysis

For region-based meta-analysis, we used the comb-p method²⁹. Briefly, comb-p takes single CpG *P*-values and locations of the CpG sites to scan the genome for regions enriched with a series of adjacent low *P*-values. In our analysis, we used *P*-values from the meta-analysis of the FHS9 and ADNI datasets as input for comb-p. We used parameter settings with --seed 0.05 and --dist 750 (a *P*-value of 0.05 is required to start a region and extend the region if another *P*-value was within 750 base pairs), which were shown to have optimal statistical properties in our previous comprehensive assessment of the comb-p software³⁰. As comb-p uses the Sidak method to account for multiple comparisons, we selected DMRs with Sidak *P*-values less than 0.05. To help reduce false positives, we imposed two additional criteria in our final selection of DMRs: (1) the DMR also has a nominal *P*-value < 1×10^{-5} ; (2) all the CpGs within the DMR have a consistent direction of change in estimated effect sizes in the meta-analysis.

Functional annotation of significant methylation associations

The significant methylation at individual CpGs and DMRs were annotated using both the Illumina (UCSC) gene annotation and Genomic Regions Enrichment of Annotations Tool (GREAT) software³¹ which associates genomic regions with target genes. To assess the overlap between our significant CpGs and DMRs (CpG or DMR location +/-250bp) with enhancers, we used enhancer gene maps generated from 131 human cell types and tissues described in Nasser et al.³², available at <https://www.engreitzlab.org/resources/>. Specifically, we selected enhancer-gene pairs with “positive” predictions from the ABC model, which included only expressed target genes, did not include promoter elements, and had an ABC score higher than 0.015. In addition, we also required that the enhancer-gene pairs be identified in cell lines relevant to this study (<https://github.com/TransBioInfoLab/AD-meta-analysis-blood/blob/main/code/annotations/>).

Pathway analysis

To identify biological pathways enriched with significant DNA methylation differences, we used the methylRRA function in the methylGSA R package³³, which used P -values from the meta-analysis of FHS9 and ADNI datasets as input. Briefly, methylGSA first computes a gene-wise ρ value by aggregating P -values from multiple CpGs mapped to each gene. Next, the different number of CpGs on each gene is adjusted by Bonferroni correction. Finally, a Gene Set Enrichment Analysis³⁴ (in pre-rank analysis mode) is performed to identify pathways enriched with significant CpGs. We analyzed pathways in the KEGG and REACTOME databases. Pathways with FDR less than 0.05 were considered to be statistically significant.

Integrative analyses with gene expression, genetic variants, and brain-to-blood correlations

To evaluate the effect of DNA methylation on the expression of nearby genes, we overlapped our dementia-associated CpGs, including both significant individual CpGs and those located within DMRs, with eQTM analysis results in Supplementary Tables 2 and 3 of Yao et al. (2021)³⁵.

For correlation and overlap with genetic susceptibility loci, We searched for mQTLs in the blood using the GoDMC database¹⁷ (<http://mqtl.db.godmc.org.uk/downloads>). To select significant blood mQTLs in GoDMC, we used the same criteria as the original study³⁶, that is, considering a cis P -value smaller than 10^{-8} and a trans P -value smaller than 10^{-14} as significant. The genome-wide summary statistics for genetic variants associated with dementia described in Bellenguez et al. (2022)³⁷ were obtained from the European Bioinformatics Institute GWAS Catalog (<https://www.ebi.ac.uk/gwas/>) under accession no. GCST90027158. Colocalization analysis was performed using the coloc R package.

To assess the correlation of dementia-associated CpGs and DMRs methylation levels in blood and brain samples, we used the London dataset, which consisted of 69 samples with matched PFC and blood samples³⁸. We assessed the association of brain and blood methylation levels at dementia-associated CpGs using both an unadjusted correlation analysis with methylation beta values (r_{beta}), and an adjusted correlation analysis using methylation residuals (r_{resid}), in which we removed the effect of estimated neuron proportions in brain samples (or estimated immune cell-type proportions in blood samples), array, age at death (for brain samples) or age at blood draw (for blood samples), and sex.

Sensitivity analysis

We evaluated if dementia risk factors would likely confound the DNA methylation to dementia associations we observed. To this end, we first performed regression analysis to assess the association between dementia-

associated CpGs (both significant individual CpGs and those located in DMRs) and dementia risk factors collected by the Framingham study, including diabetes, blood pressure, years of education, obesity, and smoking. Specifically, for each risk factor and each CpG, we fitted the model $\text{methylation.m.value} \sim \text{risk factor} + \text{age} + \text{sex} + \text{cell type proportions (B, NK, CD4T, Mono, Gran)}$. A risk factor is considered significantly associated with a CpG if its P -value is less than 0.05 in the above model (i.e., a significant risk factor for a CpG).

Next, the confounding effects of these significant risk factors for the dementia-associated CpGs were evaluated by fitting the Cox proportional regression model that expanded Model 1 above by additionally including the significant risk factor: $\text{Surv(incident dementia, follow-up time)} \sim \text{methylation.beta} + \text{risk factor} + \text{age} + \text{sex} + \text{immune cell-type proportions (B, NK, CD4T, Mono, Gran)}$.

To evaluate the impact of family structure in the discovery of significant CpGs, we computed the intraclass correlation coefficient (ICC) for dementia-associated CpGs, by fitting a random effects model $\text{methylation m-value} \sim \text{random (family)}$ to the FHS data for each CpG. The ICC was then estimated by $\frac{\sigma_u^2}{\sigma_u^2 + \sigma_e^2}$ where σ_u^2 is estimated variance component for family random effects, and σ_e^2 is the residual error. This analysis was implemented using the lmer function in the lme4 R package.

We also compared the results of Model 1 with a model that accounts for family relationships in the Cox regression model using a kinship matrix. To this end, we first computed the kinship matrix using the R package kinship2 based on the pedigree information in the dbGap dataset (accession: ph000183.v13.p14). Next, for each dementia-associated CpGs, we fitted a mixed-effects Cox regression model with a random intercept, adjusting for the same covariates as in Model 1 above in the analysis of the FHS9 dataset. The variance-covariance matrix is determined using twice the value of the kinship matrix³⁹. The mixed-effects Cox models were implemented using the coxme R package.

Validation using independent datasets

To compare our results with previous findings, we searched dementia-associated CpGs (both significant individual CpGs and those located in DMRs) using the CpG Query tool in the MIAMI-AD database⁴⁰ (<https://miami-ad.org/>). For input on phenotype, we selected “AD Biomarker”, “AD Neuropathology”, “Dementia Clinical Diagnosis”.

The external validation analysis of the methylation risk scores included 491 whole blood DNA methylation samples from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study²⁵ and 171 whole blood DNA methylation samples from the cross-European AddNeuromed study¹⁵, which were downloaded

from the GEO database (accession: GSE153712 and GSE144858). The preprocessing of DNA methylation samples from AIBL and AddNeuromed were previously described in Silva et al. (2022)⁸.

For each sample in the AIBL and the AddNeuromed datasets, we computed the methylation risk score (MRS) by summing methylation beta values for the 44 significant individual CpGs (Supplementary Table 3), weighted by their estimated effect sizes in the meta-analysis of FHS9 and ADNI study. To compare MRS between AD subjects and healthy controls, we used the Wilcoxon rank-sum test. To adjust for covariate effects, we also fitted a logistic regression model $\text{logit}(\text{Pr}(\text{AD dementia})) \sim \text{MRS} + \text{age} + \text{sex}$ using the `glm` function. To examine the association between MRS and covariates variables sex, age, and estimated cell-type proportions (B, NK, CD4T, Mono, and Gran), we computed the Spearman correlations of the MRS with age and estimated cell-type proportions. We used the Wilcoxon rank-sum test to compare MRS in female and male samples. The cell-type proportions in AIBL and AddNeuroMed datasets were estimated using the EpiDISH package.

Data and Code Availability

The genome-wide summary statistics have been deposited to the MIAMI-AD (DNA Methylation in Aging and Methylation in AD) database (<https://miami-ad.org/>). The scripts for the analyses performed in this study are available at <https://github.com/TransBioInfoLab/blood-dnam-and-incident-dementia>

RESULTS

Study cohorts

Our meta-analysis included a total of 1123 DNAm samples (measured using Illumina EPIC arrays, generated from blood samples of 907 participants (496 females, 411 males) in the Framingham Heart Study (FHS) and 216 participants (108 females, 108 males) in the Alzheimer's Disease Neuroimaging Initiative (ADNI) study (Table 1). The FHS is a transgenerational study that investigates the development of cardiovascular disease in Framingham, Massachusetts⁴¹. In the FHS, the Offspring cohort included subjects from the second generation and their spouses. In this study, we included only samples from subjects free of dementia at blood sample collection. Blood samples were collected from the offspring cohort in the FHS at Exam 9 (FHS9). The ADNI study is a longitudinal study aimed at understanding the progression of AD⁴². In the ADNI, blood samples were taken during the initial visit⁴³.

The subjects in the FHS9 were followed up to 7.72 years after Exam 9, with an average follow-up of 4.98 years, and 42 subjects developed dementia during this period. In the ADNI, the subjects were followed

for up to 11.11 years, with an average follow-up of 5.97 years, and 18 subjects developed dementia during this period. The mean ages of the participants at the time of sample collection were 72.03 years in FHS9 and 76.73 years in ADNI. The percentages of non-smokers in FHS9 and ADNI were 39.40% and 57.87%, respectively. Subjects in both cohorts are highly educated, with an average of 14.38 years of education in FHS9 and 16.36 years in ADNI.

Blood DNAm differences at individual CpGs and DMRs are significantly associated with incident dementia

After adjusting for age, sex, and immune cell type proportions, and correcting batch effects and genomic inflation (Methods), we identified 44 CpGs with a consistent direction of change in both FHS9 and ADNI datasets, a nominal *P*-value less than 0.05 in both datasets and an FDR < 0.05 in inverse-variance fixed-effects meta-analysis of the FHS9 and ADNI datasets (Figure 1, Supplementary Table 3, Supplementary Figure 1). These results remain robust in models that additionally included dementia risk factors and accounted for family structure in the FHS (see details below). For these 44 significant CpGs, the hazard ratios associated with one standard deviation change in methylation beta values ranged from 0.456 to 3.948 in the FHS9 cohort, 0.343 to 2.577 in the ADNI cohort, and 0.428 to 3.063 in the meta-analysis. About half of the significant CpGs (21 CpGs) showed hypermethylation associated with an increased risk of dementia. Also, 20 CpGs are located in CpG island or shore, and 19 CpGs are in promoter regions less than 2 kbp from the TSS.

The most significant CpG is located in the promoter of the *ICOSLG* gene, which encodes the protein Inducible T-cell COStimulator Ligand. This protein plays an important role in T-cell activation, proliferation, and cytokine production during inflammation, a key feature of dementia⁴⁴⁻⁴⁶. Among other genes associated with the top 10 most significant CpGs (Table 2), *WDR75* is involved in ribosomal biogenesis, which is crucial for protein synthesis and neuronal function^{47,48}. Our observed hypermethylation of the *WDR75* gene promoter associated with increased risk of dementia is consistent with the significant down-regulation of *WDR75* gene expression levels in the prefrontal cortex of AD brains (Agora database, log2 fold change = -0.116, adjusted *P*-value = 2.79×10^{-6}). The *MUT* gene encodes the mitochondrial matrix enzyme, methylmalnlyl-CoA mutase. Mutations in the *MUT* gene cause methylmalonic acidemia, a metabolic disorder, which can affect the brain either through direct toxicity or through secondary effects such as oxidative stress and inflammation that contribute to the neurodegenerative processes⁴⁹⁻⁵¹. The *GET4* gene modulates the contact sites between mitochondria and the endoplasmic reticulum, which are critical for calcium signaling and mitochondrial function that maintains neuronal health⁵². Finally, the *RBM14* gene encodes an RNA binding protein whose dysfunction

contributes to aberrant RNA splicing and processing, leading to neuronal degeneration in ALS and Frontotemporal dementia^{53,54}.

Using meta-analysis *P*-values for individual CpGs as input, comb-p²⁹ software identified 44 differentially methylated regions (DMRs), which had a nominal *P*-value $< 1 \times 10^{-5}$, Sidak adjusted *P*-value < 0.05 , and all the CpGs within the DMR have a consistent direction of change in estimated effect sizes in the meta-analysis (Supplementary Table 4). The number of CpGs in these DMRs ranged from 3 to 12. Among these DMRs, the majority showed hypermethylation associated with increased risk of dementia (35 DMRs), are located in CpG islands or shore (23 DMRs), or the promoter region (31 DMRs). Interestingly, among the significant individual CpGs and DMRs, 10 CpGs and 15 DMRs were also located in enhancer regions (Supplementary Table 3,4), which are regulatory DNA sequences that transcription factors bind to activate gene expression^{32,55}

The most significant DMR is located in the *PCTP* gene, which encodes the phosphatidylcholine transfer protein involved in lipid metabolism, central to many critical processes in dementia, such as blood-brain barrier function, amyloid precursor protein (APP) processing, myelination, membrane remodeling, receptor signaling, inflammation, oxidation, and energy balance⁵⁶. Notably, genetic variants on the *PCTP* gene have recently been linked to Alzheimer's dementia risk⁵⁷. Among other genes associated with the top 10 most significant DMRs (Table 3), the *MMACHC* gene is involved in the processing of vitamin B12, deficiencies of which have been associated with cognitive impairment and dementia⁵⁸. The *IRAK4* gene encodes an essential kinase in Toll-like receptor (TLR) signaling, crucial for microglial activation in response to amyloid- β (A β)⁵⁹. The *NUDT19* gene regulates mitochondrial function and energy metabolism⁶⁰, which contributes to reduced ATP production, disrupted calcium homeostasis, and increased production of reactive oxygen species (ROS) in the early stages of Alzheimer's dementia^{61,62}. The *ACY3* gene is involved in microglial responses to AD pathology⁶³, and is differentially expressed in a P301L-tau transgene mouse model⁶⁴. Moreover, a recent study identified a DMR on *ACY3* significantly associated with the progression of Alzheimer's dementia²¹.

Pathway analysis revealed DNA methylation differences associated with risk of dementia are enriched in biological pathways involved in immune responses, metabolic processes, and synaptic plasticity

To better understand biological pathways enriched with significant DNA methylation differences, we next performed pathway analysis using the methylGSA software³³. At 5% false discovery rate (FDR), we identified 28 KEGG pathways and 26 Reactome pathways (Figure 2, Table 4, Supplementary Table 5). Notably, a number of these significant pathways highlighted the central role of neuroinflammation

processes in dementia, such as *B cell receptor signaling*, *Chemokine Signaling*, *Leukocyte Transendothelial Migration*, *Fc epsilon RI signaling pathway*, *Fc gamma R-mediated phagocytosis*, *Interleukin-1 Signaling*, and *Toll-like Receptor Cascades* pathways. Also, several pathways are involved in immune responses to specific pathogens, such as *CLEC7A (Dectin-1) Signaling* that recognizes fungal infection, *Toxoplasmosis* associated with response to *Toxoplasma gondii* parasite, *influenza infection*, and *Viral Myocarditis* that respond to viral infection of the heart, which could also induce systemic inflammation and potentially affect the brain ⁶⁵.

In addition, several other significant pathways are involved in metabolic processes, including glucose and lipid metabolism, dysfunction of which are major risk factors for dementia ^{66,67}. These significant pathways include *Glycolysis / Gluconeogenesis*, *Insulin signaling*, and *Steroid biosynthesis*. Moreover, these results also pointed to synaptic plasticity critical to learning and memory, which includes significant pathways such as *Neurotrophin Signaling* ⁶⁸, *Rho GTPase signaling* ⁶⁹, and *VEGF signaling pathway* ⁷⁰. Other critical processes associated with dementia include Cell cycle ⁷¹, Endocytosis ⁷², Ribosome dysfunction ⁷³, and mRNA Splicing ⁷⁴.

Correlation of significant DNAm differences with expression of nearby genes

To better understand the functional role of the significant DMRs and CpGs, we performed several comparative analyses. We first overlapped our significant DNAm differences with previously established DNAm to RNA associations (i.e., eQTm) which was identified using matched DNA methylation and gene expression data from the Framingham study ³⁵. Among the 44 significant individual CpGs and those within the 44 DMRs, we found 13 and 15 CpGs significantly correlated with target gene expression in *cis* (i.e., within 500k bp of the CpG) or *trans*, respectively (Supplementary Table 6).

Notably, all the CpGs with *cis* associations are negatively correlated with their target gene expressions. Among them, 6 CpGs in the promoter regions of the *KIF16B* gene are significantly associated with its gene expression. The *KIF16B* gene encodes a motor protein involved in endosomal trafficking ^{75,76}, which has been increasingly recognized as a significant contributor to the pathogenesis of Alzheimer's dementia ^{77,78}. Additionally, four CpGs located on the *RWDD2B* gene correlated significantly with *RWDD2B* gene expression. The *RWDD2B* gene was recently identified as a target for osteoarthritis (OA) risk ⁷⁹. Interestingly, a growing body of research points to a link between OA and an increased risk of dementia ⁸⁰, potentially mediated by low-grade systemic inflammation ^{81,82}. Among other significant *cis* associations, one CpG on *SLCO3A1* and 2 CpGs on *CCR5* are significantly associated with their target gene expression levels. The *SLCO3A1* gene encodes a solute carrier transporter protein and is involved in the movement of

neurotransmitters across cellular membranes in the brain. Dysregulation of neurotransmitter levels can contribute to neurodegenerative diseases including dementia⁸³. The *CCR5* gene encodes a receptor found on the surface of white blood cells and is involved in the signaling pathways that regulate immune response to neuroinflammation^{84,85}, which has been associated with cognitive decline in various forms of dementia^{46,86}. These results highlight the DNAm that directly influences nearby target gene expression, potentially contributing to the pathogenesis of dementia.

Correlation and overlap with genetic risk loci

We identified methylation quantitative trait loci (mQTLs) by comparing our dementia-associated CpGs with blood mQTLs from the GoDMC database³⁶. Among the 44 significant CpGs (Supplementary Table 3) and the 233 CpGs located in significant DMRs (Supplementary Table 4), 96 CpGs had 20974 mQTLs in *cis* and 12 CpGs had 1464 mQTLs in *trans* in the blood (Supplementary Table 7).

Next, we evaluated if the mQTLs overlapped with genetic risk loci implicated in dementia, by comparing them with the genetic variants nominated in a recent AD RD meta-analysis³⁷. We found that while no mQTLs overlapped with the genome-wide significant loci, 272 SNPs overlapped with genetic variants reaching a suggestive genome-wide significance threshold at $P < 10^{-5}$ (Supplementary Table 8).

Given the observed overlap between the mQTLs and AD RD genetic risk loci, we next sought to determine whether the association signals at these loci (variant to CpG methylation levels and variant to clinical AD RD status) were due to a single shared causal variant or distinct causal variants close to each other. To this end, we performed a co-localization analysis using the method described by Giambartolomei et al. (2014)⁸⁷. The results of this co-localization analysis strongly suggested⁸⁸ (i.e. $PP3+PP4 > 0.90$, $PP4 > 0.8$ and $PP4/PP3 > 5$) that 9 genomic regions included a single causal variant common to both phenotypes (i.e. AD RD status and CpG methylation levels). The CpGs associated with these causal variants are located in the *IL34*, *C6orf25*, *ARMC5*, and *CCR5* genes (Supplementary Table 9).

Correlation of dementia-associated CpGs and DMRs methylation levels in blood and brain samples

As dementia is a brain disorder, we sought to prioritize methylation differences with a consistent direction of change in both blood and brain. To this end, we computed Spearman rank correlations between DNA methylation levels in the brain and blood using the London dataset¹⁰, which included matched DNA methylation samples measured on postmortem brain and pre-mortem blood samples of 69 subjects³⁸. We performed an adjusted correlation analysis based on methylation residuals (r_{resid}), obtained after removing effects of estimated neuron proportions for brain samples (or estimated blood cell-type proportions), batch,

age at death (for brain samples) or at blood draw (for blood samples), and sex, as well as an unadjusted correlation analysis based on methylation beta values (r_{beta}).

Among the significant individual CpGs and CpGs mapped within the DMRs, only 8 CpGs showed significant brain-to-blood associations in both adjusted and unadjusted analyses ($FDR_{beta} < 0.05$, $FDR_{resid} < 0.05$) (Supplementary Table 10). All of these CpGs were located in DMRs, and 6 out of 8 CpGs showed significant brain-to-blood positive correlations. Notably, the three CpGs with the most significant brain-to-blood correlations (r_{beta} : 0.821 to 0.851; FDR_{beta} 3.52×10^{-16} to 6.02×10^{-19}) are located on the *ZNF696* gene, which encodes a zinc finger protein involved in transcriptional regulation (Supplementary Figure 2). Interestingly, a recent study found that *ZNF696* gene expression is one of the most significantly down-regulated genes in brain samples infected with *Porphyromonas gingivalis*, a bacterium associated with periodontal disease and suspected to cause Alzheimer's dementia⁸⁹. This finding is consistent with our observed hypermethylation in the DMR located in the promoter region of this gene that is associated with increased dementia risk.

Sensitivity analyses

A growing body of recent research suggests that various lifestyle factors, such as smoking, may contribute to dementia^{90,91}. Meanwhile, recent studies also reported that DNA methylation is influenced by these lifestyle risk factors⁹²⁻⁹⁷. Therefore, we investigated whether any of the dementia-associated CpGs were also associated with dementia risk factors collected by the Framingham study, including *APOE*, diabetes, hypertension, years of education, BMI, and smoking. We found that among the 271 dementia-associated CpGs (44 significant individual CpGs, 233 CpGs located in significant DMRs, and 6 overlapping CpGs), 43 CpGs are associated with number of *APOE4* alleles, 28 CpGs are associated with smoking status, and 6 CpGs are associated with years of education. Moreover, 13, 18, and 7 CpGs are associated with BMI, diabetes, and hypertension status, respectively (Supplementary Table 11).

To evaluate the confounding effects of these risk factors, we re-analyzed the FHS9 dataset and performed a sensitivity analysis of the dementia-associated CpGs, by additionally adjusting for the significant risk factors they were associated with in the Cox regression model. Supplementary Table 12 shows the estimated hazard ratios (HRs) for all dementia-associated CpGs based on the original model and expanded model are very similar. Moreover, the *P*-values for the significant individual CpGs ranged from 1.20×10^{-7} to 4.02×10^{-3} in the original model and ranged from 2.20×10^{-7} to 0.0135 in the expanded model, indicating these CpGs are associated with dementia independent of the covariate factors.

A second sensitivity analysis was performed to evaluate the impact of family structure in the FHS9 dataset on our analysis results. To this end, we estimated the intraclass correlation coefficient (ICC) for the

dementia-associated CpGs, by comparing between-family variance to the total variance, which is the sum of between-family variance and within-family variance. Our results showed that for the 271 dementia-associated CpGs, the ICC values ranged from 0 to 0.149 (Supplementary Table 13), indicating minimal intraclass correlation in DNA methylation at these CpGs due to family structure.

In addition, we also performed an additional analysis using mixed-effects Cox models that accounted for family relationships with a kinship matrix computed from pedigree information. Notably, the P -values for the 44 dementia-associated individual CpGs ranged from 2.29×10^{-9} to 6.02×10^{-3} in the original model, and from 7.51×10^{-8} to 6.02×10^{-3} in the mixed effects Cox model. Supplementary Table 14 shows the hazard ratios and P -values from the mixed effects Cox model are very similar to those from the original Cox model, indicating that our results are robust to family structure in the FHS9 dataset.

Validation using independent datasets

To validate our findings, we compared our dementia-associated CpGs and DMRs with those identified in previous studies using our recently developed MIAMI-AD database⁴⁰ (<https://miami-ad.org/>). Our comparison revealed that 17 of the 44 significant individual CpGs (38.6%) overlapped with significant findings in previous research, with consistent direction of change (Supplementary Table 15). These corroborated CpGs are located in the promoter regions of the *ICOSLG*, *WDR75*, *MUT*, *SLCO3A1*, *TARSL2*, *SLC12A2*, *NCAM1*, and *RASSF8* genes, as well as intergenic regions. Similarly, among the 227 CpGs located in DMRs, 65 CpGs (28.6%), found in the promoter regions of the *ACY3*, *ARMC5*, *CCR5*, *DNAJB4*, *GET4*, *GLRX*, *TEX12*, *KIF16B*, *LRRC59*, *C6orf25*, *MMACHC*, *HES5*, *PCTP*, *PLA2G1B*, *IRAK4*, *SLCO3A1*, *UBE2Q2*, *VAV1*, *ZMAT2*, and *ZNF696* genes, and intergenic regions, were supported by previous research, also showing the same direction of effect.

In addition, we also evaluated the ability of methylation risk scores (MRS)⁹⁸ computed based on our significant CpGs (Supplementary Table 3) for distinguishing AD subjects from controls in two independent datasets. These datasets were generated by the Australian Imaging, Biomarkers, and Lifestyle (AIBL)⁹⁹ ($n = 491$) and AddNeuroMed¹⁰⁰ studies ($n = 171$), and included blood DNAm samples of healthy controls and Alzheimer's dementia subjects.

For each sample in these two independent datasets, the MRS was computed by summing up the methylation beta values of the 44 dementia-associated CpGs weighted by their estimated effect sizes in the meta-analysis of FHS9 and ADNI study datasets. Figure 3 shows the MRS values are significantly different between healthy controls and AD subjects in both AIBL (P -value = 0.0026) and AddNeuroMed (P -value = 0.020) datasets. After adjusting for age and sex, MRS is no longer significant in the AIBL dataset but remained significant in the AddNeuroMed dataset (P -value = 0.035).

To better understand the MRS, we next examined its associations with age, sex, and estimated immune cell type proportions in the samples. In both the FHS9 and ADNI cohorts, MRS showed a significant association with age, sex, as well as B and granulocyte cell type proportions (Supplementary Table 16). These results are consistent with recent literature that highlights DNA methylation changes related to aging and sex differences¹⁰¹⁻¹¹⁰, as well as the significant increase in granulocytes and decrease in B cells associated with inflammatory responses in dementia^{7,25,111-114}.

DISCUSSION

We performed a comprehensive analysis of more than 1000 blood samples to identify DNA methylation associated with incident dementia in two longitudinal studies. After correcting for multiple comparisons, we identified 44 CpGs and 44 DMRs significantly associated with dementia risk (Supplementary Tables 3-4). Comparing these significant DNAm differences with findings from previous cross-sectional studies, we found that approximately 40% of the significant CpGs and 30% of the DMRs overlapped with previous results. This discrepancy suggests that some DNAm differences observed in cross-sectional studies may be due to reverse causation of the disease. The novel DNAm differences discovered in this study highlighted the importance of using a longitudinal design to identify DNAm changes with a temporal relationship to the disease.

Importantly, a number of our findings pointed to early processes in dementia, where DNA methylation could serve as biomarkers and potential therapeutic targets can be developed. For example, our results confirmed the central role of neuroinflammation in dementia¹¹⁵⁻¹¹⁷, including immune responses to dementia pathology such as amyloid beta, which may be deposited in the brain decades before the onset of clinical symptoms¹¹⁸. Our most significant CpG is located on the *ICOSLG* gene associated with T-cell activation⁴⁴⁻⁴⁶. Additionally, two of the top 10 most significant DMRs are located on the *IRAK4* and *ACY3* genes, which are associated with microglia activation^{59,63}. Our pathway analysis also pointed to immune responses to dementia pathology, highlighting pathways such as *B cell receptor signaling*, *Chemokine Signaling*, *Leukocyte Transendothelial Migration*, *Interleukin-1 Signaling*, and *Toll-like Receptor Cascades*. It has been proposed that reducing neuroinflammation may be a promising strategy for delaying the onset and progression of neurodegenerative diseases^{119,120}.

Our results also underscore the role of metabolic dysfunction as an early event in dementia, well before significant amyloid-beta protein accumulation^{121,122}, which is consistent with late-onset diabetes being an established risk factor for dementia¹²³. Our most significant DNAm included CpGs and DMRs located on the *MUT*, *GET4*, and *NUDT19* genes which are crucial for mitochondrial function and energy metabolism. The most significant DMR is located in the *PCTP* gene involved in lipid metabolism, which is increasingly

recognized for its important role in Alzheimer's dementia¹²⁴. Our pathway analysis also highlighted a number of metabolic processes, including *glycolysis/gluconeogenesis*, *insulin signaling*, and *steroid biosynthesis*. Impairments in these pathways lead to energy deficits, oxidative stress, synaptic dysfunction, and inflammation, which are early hallmarks of neurodegeneration. Encouragingly, recent research suggests that targeting mitochondria may offer promising therapeutic targets for the treatment and prevention of dementia¹²⁵. In model organisms, the removal of defective mitochondria diminishes insoluble A β ₁₋₄₂ and reverses memory impairment¹²⁶, and treatment with anti-diabetes drugs reduces protein aggregation and reverses A β -induced metabolic defects¹²⁷. Moreover, in patients, insulin treatment improved cognitive function in subjects with mild cognitive impairment¹²⁸.

The strengths of this study include the longitudinal design of the FHS and ADNI studies, which allowed us to identify DNAm associated with incident dementia. In both studies, dementia status was adjudicated by a team of experts based on comprehensive data, including clinical assessments, cognitive testing, and biomarkers. To reduce concerns of false positives, we adjusted for potential confounding effects such as age, sex, estimated major immune cell-type proportions in the blood, and batch effects in all our analyses. We also performed inflation correction using the bacon method²⁸, specifically designed for epigenome-wide association studies. Additionally, we used stringent criteria to select our significant CpGs and DMRs. For significant individual CpGs, we required consistent directional effects and nominal significance in both cohorts. For DMRs, we required all CpGs within the DMR to have consistent directional effects. Moreover, we evaluated the sensitivity of our results to major risk factors of dementia, some of which also correlated with DNA methylation. We found that all of our 44 dementia-associated CpGs remained significant, indicating their association with dementia is independent of the risk factors. We also estimated intraclass correlation coefficients and performed additional analyses accounting for family relationships in FHS9 using a kinship matrix. The results of this analysis showed our findings are robust to family structure in the FHS9 dataset. Finally, the DNAm samples in both ADNI and FHS9 studies were measured using Illumina EPIC arrays, which provide improved coverage of regulatory elements¹²⁹ and were recently shown to generate more reliable DNA methylation levels than the older 450k arrays¹³⁰.

This study also has several limitations. First, we analyzed bulk blood DNA methylation samples, which contain a mixture of cell types. To reduce confounding effects due to different cell types, we included estimated cell-type proportions as covariate variables in all our analyses. Future studies utilizing single-cell technology would provide more insight into the specific cell types affected by the dementia-associated DNA methylation differences discovered in this study. Second, due to the lack of data, we analyzed only DNA methylation samples from non-Hispanic white subjects, and the subjects in both cohorts were highly educated. Future studies that investigate DNA methylation in large, multi-ethnic cohorts with diverse backgrounds are needed. Finally, while both ADNI and FHS have dementia surveillance programs, the

insidious onset of dementia might lead to underreporting, with some subjects reaching dementia status before their recorded onset date. These cases could dilute the association signals between DNA methylation and incident dementia in our study, making our meta-analysis results conservative. It has been estimated that a substantial proportion of dementia cases may be undiagnosed or not reported². Therefore, a sensitive and objective biomarker, such as DNA methylation that can be easily quantified, is urgently needed to help improve surveillance of incident dementia.

In summary, we identified numerous DNA methylation differences consistently associated with incident dementia in a meta-analysis of two longitudinal cohorts, comprising over 1,000 blood samples. Our comparative analysis, which incorporated results from integrative analysis of blood DNA methylation with gene expression, genetic variants, and brain DNA methylation data, and pathway enrichment analysis highlights the central role of neuroinflammation in dementia. Importantly, our analysis also revealed that early processes such as metabolic dysfunction are marked by DNA methylation in the blood, nominating blood DNAm as a plausible objective biomarker for identifying individuals at higher risk for dementia. Future studies that validate our findings in larger and more diverse community-based cohorts are warranted.

References

1. Hurd, M.D., Martorell, P., Delavande, A., Mullen, K.J. & Langa, K.M. Monetary costs of dementia in the United States. *N Engl J Med* **368**, 1326-34 (2013).
2. Ty, D. & Ahuja, R. Projected Prevalence and Cost of Dementia: 2022 Update https://millkeninstitute.org/sites/default/files/2022-11/Projected%20Prevalence%20and%20Cost%20of%20Dementia%202022%20Update_Highlights_FINAL_Nov.pdf. (2022).
3. Zissimopoulos, J., Crimmins, E. & St Clair, P. The Value of Delaying Alzheimer's Disease Onset. *Forum Health Econ Policy* **18**, 25-39 (2014).
4. Mikeska, T. & Craig, J.M. DNA methylation biomarkers: cancer and beyond. *Genes (Basel)* **5**, 821-64 (2014).
5. Zhang, L. *et al.* Epigenome-wide meta-analysis of DNA methylation differences in prefrontal cortex implicates the immune processes in Alzheimer's disease. *Nat Commun* **11**, 6114 (2020).
6. Zhang, L. *et al.* Sex-specific DNA methylation differences in Alzheimer's disease pathology. *Acta Neuropathol Commun* **9**, 77 (2021).
7. T, C.S. *et al.* Distinct sex-specific DNA methylation differences in Alzheimer's disease. *Alzheimers Res Ther* **14**, 133 (2022).
8. T, C.S. *et al.* Cross-tissue analysis of blood and brain epigenome-wide association studies in Alzheimer's disease. *Nat Commun* **13**, 4852 (2022).
9. De Jager, P.L. *et al.* Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. *Nat Neurosci* **17**, 1156-63 (2014).
10. Lunnon, K. *et al.* Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. *Nat Neurosci* **17**, 1164-70 (2014).
11. Smith, R.G. *et al.* Elevated DNA methylation across a 48-kb region spanning the HOXA gene cluster is associated with Alzheimer's disease neuropathology. *Alzheimers Dement* **14**, 1580-1588 (2018).
12. Smith, R.G. *et al.* A meta-analysis of epigenome-wide association studies in Alzheimer's disease highlights novel differentially methylated loci across cortex. *Nat Commun* **12**, 3517 (2021).
13. Fransquet, P.D. *et al.* Blood DNA methylation as a potential biomarker of dementia: A systematic review. *Alzheimers Dement* **14**, 81-103 (2018).
14. Kobayashi, N. *et al.* Increased blood COASY DNA methylation levels a potential biomarker for early pathology of Alzheimer's disease. *Sci Rep* **10**, 12217 (2020).
15. Roubroeks, J.A.Y. *et al.* An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene. *Neurobiol Aging* **95**, 26-45 (2020).
16. Fransquet, P.D. *et al.* DNA methylation analysis of candidate genes associated with dementia in peripheral blood. *Epigenomics* **12**, 2109-2123 (2020).
17. Madrid, A. *et al.* DNA Hypomethylation in Blood Links B3GALT4 and ZADH2 to Alzheimer's Disease. *J Alzheimers Dis* **66**, 927-934 (2018).
18. Mitsumori, R. *et al.* Lower DNA methylation levels in CpG island shores of CR1, CLU, and PICALM in the blood of Japanese Alzheimer's disease patients. *PLoS One* **15**, e0239196 (2020).
19. Roubroeks, J.A.Y., Smith, R.G., van den Hove, D.L.A. & Lunnon, K. Epigenetics and DNA methylomic profiling in Alzheimer's disease and other neurodegenerative diseases. *J Neurochem* **143**, 158-170 (2017).
20. Fransquet, P.D. *et al.* Blood DNA methylation signatures to detect dementia prior to overt clinical symptoms. *Alzheimers Dement (Amst)* **12**, e12056 (2020).
21. Li, Q.S. *et al.* Association of peripheral blood DNA methylation level with Alzheimer's disease progression. *Clin Epigenetics* **13**, 191 (2021).

22. Schafer Hackenhaar, F. *et al.* Sixteen-Year Longitudinal Evaluation of Blood-Based DNA Methylation Biomarkers for Early Prediction of Alzheimer's Disease. *J Alzheimers Dis* **94**, 1443-1464 (2023).
23. Giannini, L.A.A. *et al.* Distinctive cell-free DNA methylation characterizes presymptomatic genetic frontotemporal dementia. *Ann Clin Transl Neurol* **11**, 744-756 (2024).
24. Chen, Y.A. *et al.* Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. *Epigenetics* **8**, 203-9 (2013).
25. Nabais, M.F. *et al.* Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. *Genome Biol* **22**, 90 (2021).
26. Akulenko, R., Merl, M. & Helms, V. BEclear: Batch Effect Detection and Adjustment in DNA Methylation Data. *PLoS One* **11**, e0159921 (2016).
27. Delvin, B. & Roeder, K. Genomic Control for Association Studies. *Biometrics* **55**, 997-1004 (1999).
28. van Iterson, M., van Zwet, E.W., Consortium, B. & Heijmans, B.T. Controlling bias and inflation in epigenome- and transcriptome-wide association studies using the empirical null distribution. *Genome Biol* **18**, 19 (2017).
29. Pedersen, B.S., Schwartz, D.A., Yang, I.V. & Kechris, K.J. Comb-p: software for combining, analyzing, grouping and correcting spatially correlated P-values. *Bioinformatics* **28**, 2986-8 (2012).
30. Mallik, S. *et al.* An evaluation of supervised methods for identifying differentially methylated regions in Illumina methylation arrays. *Brief Bioinform* **20**, 2224-2235 (2019).
31. McLean, C.Y. *et al.* GREAT improves functional interpretation of cis-regulatory regions. *Nat Biotechnol* **28**, 495-501 (2010).
32. Nasser, J. *et al.* Genome-wide enhancer maps link risk variants to disease genes. *Nature* **593**, 238-243 (2021).
33. Ren, X. & Kuan, P.F. methylGSA: a Bioconductor package and Shiny app for DNA methylation data length bias adjustment in gene set testing. *Bioinformatics* **35**, 1958-1959 (2019).
34. Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* **102**, 15545-50 (2005).
35. Yao, C. *et al.* Epigenome-wide association study of whole blood gene expression in Framingham Heart Study participants provides molecular insight into the potential role of CHRNA5 in cigarette smoking-related lung diseases. *Clin Epigenetics* **13**, 60 (2021).
36. Min, J.L. *et al.* Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation. *Nat Genet* **53**, 1311-1321 (2021).
37. Bellenguez, C. *et al.* New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nat Genet* **54**, 412-436 (2022).
38. Hannon, E., Lunnon, K., Schalkwyk, L. & Mill, J. Interindividual methylomic variation across blood, cortex, and cerebellum: implications for epigenetic studies of neurological and neuropsychiatric phenotypes. *Epigenetics* **10**, 1024-32 (2015).
39. Therneau, T. Mixed Effects Cox Models. *R package coxme vignette*, section 4.3.
40. Lukacsovich, D. *et al.* MIAMI-AD (Methylation in Aging and Methylation in AD): an integrative knowledgebase that facilitates explorations of DNA methylation across sex, aging, and Alzheimer's disease. *medRxiv* (2023).
41. Andersson, C., Johnson, A.D., Benjamin, E.J., Levy, D. & Vasan, R.S. 70-year legacy of the Framingham Heart Study. *Nat Rev Cardiol* **16**, 687-698 (2019).
42. Veitch, D.P. *et al.* Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. *Alzheimers Dement* **15**, 106-152 (2019).

43. Vasanthakumar, A. *et al.* Harnessing peripheral DNA methylation differences in the Alzheimer's Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease. *Clin Epigenetics* **12**, 84 (2020).
44. Yoshinaga, S.K. *et al.* Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS. *Int Immunol* **12**, 1439-47 (2000).
45. Farina, M.P., Kim, J.K., Hayward, M.D. & Crimmins, E.M. Links between inflammation and immune functioning with cognitive status among older Americans in the Health and Retirement Study. *Brain Behav Immun Health* **26**, 100559 (2022).
46. Ahmad, M.A. *et al.* Neuroinflammation: A Potential Risk for Dementia. *Int J Mol Sci* **23**(2022).
47. Moudry, P., Chroma, K., Bursac, S., Volarevic, S. & Bartek, J. RNA-interference screen for p53 regulators unveils a role of WDR75 in ribosome biogenesis. *Cell Death Differ* **29**, 687-696 (2022).
48. Slomnicki, L.P. *et al.* Requirement of Neuronal Ribosome Synthesis for Growth and Maintenance of the Dendritic Tree. *J Biol Chem* **291**, 5721-5739 (2016).
49. Chandler, R.J. *et al.* Mitochondrial dysfunction in mut methylmalonic acidemia. *FASEB J* **23**, 1252-61 (2009).
50. Li, Q. *et al.* Determination of Cytokines and Oxidative Stress Biomarkers in Cognitive Impairment Induced by Methylmalonic Acidemia. *Neuroimmunomodulation* **28**, 178-186 (2021).
51. Yuan, Y. *et al.* Clinical and electroencephalogram characteristics of methylmalonic acidemia with MMACHC and MUT gene mutations. *BMC Pediatr* **24**, 119 (2024).
52. Wilson, E.L. *et al.* Genome-wide CRISPR/Cas9 screen shows that loss of GET4 increases mitochondria-endoplasmic reticulum contact sites and is neuroprotective. *Cell Death Dis* **15**, 203 (2024).
53. Ravanidis, S., Kattan, F.G. & Doxakis, E. Unraveling the Pathways to Neuronal Homeostasis and Disease: Mechanistic Insights into the Role of RNA-Binding Proteins and Associated Factors. *Int J Mol Sci* **19**(2018).
54. Satoh, J. *et al.* Molecular network analysis suggests a logical hypothesis for the pathological role of c9orf72 in amyotrophic lateral sclerosis/frontotemporal dementia. *J Cent Nerv Syst Dis* **6**, 69-78 (2014).
55. Mukherjee, S., Erickson, H. & Bastia, D. Enhancer-origin interaction in plasmid R6K involves a DNA loop mediated by initiator protein. *Cell* **52**, 375-83 (1988).
56. Chew, H., Solomon, V.A. & Fonteh, A.N. Involvement of Lipids in Alzheimer's Disease Pathology and Potential Therapies. *Front Physiol* **11**, 598 (2020).
57. Jones, L. *et al.* Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. *PLoS One* **5**, e13950 (2010).
58. Hannibal, L. *et al.* The MMACHC proteome: hallmarks of functional cobalamin deficiency in humans. *Mol Genet Metab* **103**, 226-39 (2011).
59. Cameron, B. *et al.* Loss of interleukin receptor-associated kinase 4 signaling suppresses amyloid pathology and alters microglial phenotype in a mouse model of Alzheimer's disease. *J Neurosci* **32**, 15112-23 (2012).
60. Gorigk, S. *et al.* Nudix hydrolase NUDT19 regulates mitochondrial function and ATP production in murine hepatocytes. *Biochim Biophys Acta Mol Cell Biol Lipids* **1867**, 159153 (2022).
61. Misrani, A., Tabassum, S. & Yang, L. Mitochondrial Dysfunction and Oxidative Stress in Alzheimer's Disease. *Front Aging Neurosci* **13**, 617588 (2021).
62. Tobore, T.O. On the central role of mitochondria dysfunction and oxidative stress in Alzheimer's disease. *Neurol Sci* **40**, 1527-1540 (2019).
63. Srinivasan, K. *et al.* Alzheimer's Patient Microglia Exhibit Enhanced Aging and Unique Transcriptional Activation. *Cell Rep* **31**, 107843 (2020).

64. Bonham, L.W., Sirkis, D.W. & Yokoyama, J.S. The Transcriptional Landscape of Microglial Genes in Aging and Neurodegenerative Disease. *Front Immunol* **10**, 1170 (2019).
65. Trifan, G. & Testai, F.D. Neurological Manifestations of Myocarditis. *Curr Neurol Neurosci Rep* **22**, 363-374 (2022).
66. Craft, S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. *Arch Neurol* **66**, 300-5 (2009).
67. Ezkurdia, A., Ramirez, M.J. & Solas, M. Metabolic Syndrome as a Risk Factor for Alzheimer's Disease: A Focus on Insulin Resistance. *Int J Mol Sci* **24**(2023).
68. Gomez-Palacio-Schjetnan, A. & Escobar, M.L. Neurotrophins and synaptic plasticity. *Curr Top Behav Neurosci* **15**, 117-36 (2013).
69. Zhang, H., Ben Zablah, Y., Zhang, H. & Jia, Z. Rho Signaling in Synaptic Plasticity, Memory, and Brain Disorders. *Front Cell Dev Biol* **9**, 729076 (2021).
70. Tillo, M., Ruhrberg, C. & Mackenzie, F. Emerging roles for semaphorins and VEGFs in synaptogenesis and synaptic plasticity. *Cell Adh Migr* **6**, 541-6 (2012).
71. Herrup, K. The involvement of cell cycle events in the pathogenesis of Alzheimer's disease. *Alzheimers Res Ther* **2**, 13 (2010).
72. Zadka, L. *et al.* Endocytosis and Alzheimer's disease. *Geroscience* **46**, 71-85 (2024).
73. Ding, Q., Markesbery, W.R., Chen, Q., Li, F. & Keller, J.N. Ribosome dysfunction is an early event in Alzheimer's disease. *J Neurosci* **25**, 9171-5 (2005).
74. Li, D., McIntosh, C.S., Mastaglia, F.L., Wilton, S.D. & Aung-Htut, M.T. Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies. *Transl Neurodegener* **10**, 16 (2021).
75. Li, B.J. *et al.* PX Domain-Containing Kinesin KIF16B and Microtubule-Dependent Intracellular Movements. *J Membr Biol* **253**, 101-108 (2020).
76. Farkhondeh, A., Niwa, S., Takei, Y. & Hirokawa, N. Characterizing KIF16B in neurons reveals a novel intramolecular "stalk inhibition" mechanism that regulates its capacity to potentiate the selective somatodendritic localization of early endosomes. *J Neurosci* **35**, 5067-86 (2015).
77. Limone, A., Veneruso, I., D'Argenio, V. & Sarnataro, D. Endosomal trafficking and related genetic underpinnings as a hub in Alzheimer's disease. *J Cell Physiol* **237**, 3803-3815 (2022).
78. Small, S.A., Simoes-Spassov, S., Mayeux, R. & Petsko, G.A. Endosomal Traffic Jams Represent a Pathogenic Hub and Therapeutic Target in Alzheimer's Disease. *Trends Neurosci* **40**, 592-602 (2017).
79. Parker, E. *et al.* Multi-Tissue Epigenetic and Gene Expression Analysis Combined With Epigenome Modulation Identifies RWDD2B as a Target of Osteoarthritis Susceptibility. *Arthritis Rheumatol* **73**, 100-109 (2021).
80. Weber, A. *et al.* Association between osteoarthritis and increased risk of dementia: A systemic review and meta-analysis. *Medicine (Baltimore)* **98**, e14355 (2019).
81. Umoh, I.O., Dos Reis, H.J. & de Oliveira, A.C.P. Molecular Mechanisms Linking Osteoarthritis and Alzheimer's Disease: Shared Pathways, Mechanisms and Breakthrough Prospects. *Int J Mol Sci* **25**(2024).
82. Guo, R. *et al.* The Association Between Osteoarthritis with Risk of Dementia and Cognitive Impairment: A Meta-Analysis and Systematic Review. *J Alzheimers Dis* **89**, 1159-1172 (2022).
83. Ayka, A. & Sehirli, A.O. The Role of the SLC Transporters Protein in the Neurodegenerative Disorders. *Clin Psychopharmacol Neurosci* **18**, 174-187 (2020).
84. Li, T. & Zhu, J. Entanglement of CCR5 and Alzheimer's Disease. *Front Aging Neurosci* **11**, 209 (2019).
85. Ma, W. *et al.* The intricate role of CCL5/CCR5 axis in Alzheimer disease. *J Neuropathol Exp Neurol* **82**, 894-900 (2023).

86. Lempriere, S. Neuroinflammation predicts cognitive decline in FTD. *Nat Rev Neurol* **19**, 258 (2023).
87. Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS Genet* **10**, e1004383 (2014).
88. Guo, H. *et al.* Integration of disease association and eQTL data using a Bayesian colocalisation approach highlights six candidate causal genes in immune-mediated diseases. *Hum Mol Genet* **24**, 3305-13 (2015).
89. Patel, S. *et al.* Characterization of Human Genes Modulated by *Porphyromonas gingivalis* Highlights the Ribosome, Hypothalamus, and Cholinergic Neurons. *Front Immunol* **12**, 646259 (2021).
90. Livingston, G. *et al.* Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet* **396**, 413-446 (2020).
91. Ranson, J.M. *et al.* Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services-part 2 of 6. *Alzheimers Res Ther* **13**, 169 (2021).
92. Walker, R.M. *et al.* Epigenome-wide analyses identify DNA methylation signatures of dementia risk. *Alzheimers Dement (Amst)* **12**, e12078 (2020).
93. Philibert, R.A., Beach, S.R. & Brody, G.H. The DNA methylation signature of smoking: an archetype for the identification of biomarkers for behavioral illness. *Nebr Symp Motiv* **61**, 109-27 (2014).
94. Demura, M. & Saijoh, K. The Role of DNA Methylation in Hypertension. *Adv Exp Med Biol* **956**, 583-598 (2017).
95. Raciti, G.A. *et al.* DNA Methylation and Type 2 Diabetes: Novel Biomarkers for Risk Assessment? *Int J Mol Sci* **22**(2021).
96. Sambblas, M., Milagro, F.I. & Martinez, A. DNA methylation markers in obesity, metabolic syndrome, and weight loss. *Epigenetics* **14**, 421-444 (2019).
97. Zhao, W. *et al.* Education and Lifestyle Factors Are Associated with DNA Methylation Clocks in Older African Americans. *Int J Environ Res Public Health* **16**(2019).
98. Huls, A. & Czamara, D. Methodological challenges in constructing DNA methylation risk scores. *Epigenetics* **15**, 1-11 (2020).
99. Ellis, K.A. *et al.* The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. *Int Psychogeriatr* **21**, 672-87 (2009).
100. Lovestone, S. *et al.* AddNeuroMed--the European collaboration for the discovery of novel biomarkers for Alzheimer's disease. *Ann N Y Acad Sci* **1180**, 36-46 (2009).
101. Bell, C.G. *et al.* Novel regional age-associated DNA methylation changes within human common disease-associated loci. *Genome Biol* **17**, 193 (2016).
102. Day, K. *et al.* Differential DNA methylation with age displays both common and dynamic features across human tissues that are influenced by CpG landscape. *Genome Biol* **14**, R102 (2013).
103. Johansson, A., Enroth, S. & Gyllenstein, U. Continuous Aging of the Human DNA Methylome Throughout the Human Lifespan. *PLoS One* **8**, e67378 (2013).
104. Bacalini, M.G. *et al.* A meta-analysis on age-associated changes in blood DNA methylation: results from an original analysis pipeline for Infinium 450k data. *Aging (Albany NY)* **7**, 97-109 (2015).
105. Reynolds, L.M. *et al.* Age-related variations in the methylome associated with gene expression in human monocytes and T cells. *Nat Commun* **5**, 5366 (2014).
106. Ferretti, M.T. *et al.* Sex differences in Alzheimer disease - the gateway to precision medicine. *Nat Rev Neurol* **14**, 457-469 (2018).

107. Mazure, C.M. & Swendsen, J. Sex differences in Alzheimer's disease and other dementias. *Lancet Neurol* **15**, 451-2 (2016).
108. Nebel, R.A. *et al.* Understanding the impact of sex and gender in Alzheimer's disease: A call to action. *Alzheimers Dement* **14**, 1171-1183 (2018).
109. Hampel, H. *et al.* Precision medicine and drug development in Alzheimer's disease: the importance of sexual dimorphism and patient stratification. *Front Neuroendocrinol* **50**, 31-51 (2018).
110. Lin, K.A. & Doraiswamy, P.M. When Mars Versus Venus is Not a Cliche: Gender Differences in the Neurobiology of Alzheimer's Disease. *Front Neurol* **5**, 288 (2014).
111. Zenaro, E. *et al.* Neutrophils promote Alzheimer's disease-like pathology and cognitive decline via LFA-1 integrin. *Nat Med* **21**, 880-6 (2015).
112. Busse, M. *et al.* Alterations in the Peripheral Immune System in Dementia. *J Alzheimers Dis* **58**, 1303-1313 (2017).
113. Xiong, L.L. *et al.* Single-cell RNA sequencing reveals B cell-related molecular biomarkers for Alzheimer's disease. *Exp Mol Med* **53**, 1888-1901 (2021).
114. Pellicano, M. *et al.* Systemic immune responses in Alzheimer's disease: in vitro mononuclear cell activation and cytokine production. *J Alzheimers Dis* **21**, 181-92 (2010).
115. Heneka, M.T. *et al.* Neuroinflammation in Alzheimer's disease. *Lancet Neurol* **14**, 388-405 (2015).
116. Heppner, F.L., Ransohoff, R.M. & Becher, B. Immune attack: the role of inflammation in Alzheimer disease. *Nat Rev Neurosci* **16**, 358-72 (2015).
117. Ransohoff, R.M. How neuroinflammation contributes to neurodegeneration. *Science* **353**, 777-83 (2016).
118. Beason-Held, L.L. *et al.* Changes in brain function occur years before the onset of cognitive impairment. *J Neurosci* **33**, 18008-14 (2013).
119. Esposito, M. & Sherr, G.L. Epigenetic Modifications in Alzheimer's Neuropathology and Therapeutics. *Front Neurosci* **13**, 476 (2019).
120. Zhang, W., Xiao, D., Mao, Q. & Xia, H. Role of neuroinflammation in neurodegeneration development. *Signal Transduct Target Ther* **8**, 267 (2023).
121. Ye, X., Tai, W. & Zhang, D. The early events of Alzheimer's disease pathology: from mitochondrial dysfunction to BDNF axonal transport deficits. *Neurobiol Aging* **33**, 1122 e1-10 (2012).
122. Yao, J. *et al.* Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. *Proc Natl Acad Sci U S A* **106**, 14670-5 (2009).
123. Cholerton, B., Baker, L.D., Montine, T.J. & Craft, S. Type 2 Diabetes, Cognition, and Dementia in Older Adults: Toward a Precision Health Approach. *Diabetes Spectr* **29**, 210-219 (2016).
124. Huang, W. *et al.* An immune response characterizes early Alzheimer's disease pathology and subjective cognitive impairment in hydrocephalus biopsies. *Nat Commun* **12**, 5659 (2021).
125. Lanzillotta, C., Di Domenico, F., Perluigi, M. & Butterfield, D.A. Targeting Mitochondria in Alzheimer Disease: Rationale and Perspectives. *CNS Drugs* **33**, 957-969 (2019).
126. Fang, E.F. *et al.* Mitophagy inhibits amyloid-beta and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. *Nat Neurosci* **22**, 401-412 (2019).
127. Teo, E. *et al.* Metabolic stress is a primary pathogenic event in transgenic *Caenorhabditis elegans* expressing pan-neuronal human amyloid beta. *Elife* **8**(2019).
128. Craft, S. *et al.* Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial. *J Alzheimers Dis* **57**, 1325-1334 (2017).
129. Pidsley, R. *et al.* Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. *Genome Biol* **17**, 208 (2016).
130. Zhang, W. *et al.* Critical evaluation of the reliability of DNA methylation probes on the Illumina MethylationEPIC v1.0 BeadChip microarrays. *Epigenetics* **19**, 2333660 (2024).

ACKNOWLEDGMENTS

Data collection and sharing for the ADNI dataset was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflicts of interest.

FUNDING SOURCES

This research was supported by US National Institutes of Health grants R61NS135587 (L.W.), RF1NS128145 (L.W.), and R01AG062634 (E.R.M, B.W.K., L.W.).

CONSENT STATEMENT

The ADNI and Framingham Heart Study were approved by the institutional review boards of all participating institutions. Written informed consent was obtained from all the participants or their authorized representatives.

KEYWORDS

dementia, DNA methylation, longitudinal study




Figure 1 Manhattan plot of significant DNA methylation differences associated with dementia in meta-analysis of FHS9 (FHS at exam 9) and ADNI datasets. The X-axis indicates chromosome number. The Y-axis shows $-\log_{10}(P\text{-value})$ of meta-analysis, with red line indicating a 5% False Discovery Rate (FDR). The genes with promoter regions containing the top 10 most significant CpGs are highlighted. The red dots correspond to the 44 CpGs with a consistent direction of change in both FHS9 and ADNI datasets, a nominal P -value less than 0.05 in both datasets, and an $FDR < 0.05$ in meta-analysis of the FHS9 and ADNI datasets.




Figure 2 Significant KEGG (A) and Reactome (B) pathways enriched with dementia-associated CpGs at false discovery rate (FDR) less than 0.05.




Figure 3 External validation of the methylation risk scores (MRS). The MRS were computed by summing up methylation beta values of the 44 dementia-associated CpGs weighted by their estimated effect sizes in the meta-analysis of FHS9 (FHS at exam 9) and ADNI study datasets. The MRS are significantly different between dementia and control subjects in external cohorts AIBL and AddNeuroMed.